J. Ledermann, N. Colombo, A. Oza, K. Fujiwara, M. Birrer, L. Randall, E. Poddubskaya, G. Scambia, YV Shparyk, M. Lim, J. Sohn, K. Yonemori, R. Stewart, Xijun Zhang, J. P. Smith, C. Linn, B. Monk
{"title":"Avelumab联合化疗和/或化疗后与化疗治疗初治卵巢癌患者:JAVELIN ovarian 100试验3期生物标志物分析","authors":"J. Ledermann, N. Colombo, A. Oza, K. Fujiwara, M. Birrer, L. Randall, E. Poddubskaya, G. Scambia, YV Shparyk, M. Lim, J. Sohn, K. Yonemori, R. Stewart, Xijun Zhang, J. P. Smith, C. Linn, B. Monk","doi":"10.1136/ijgc-2020-igcs.1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":254448,"journal":{"name":"Oral Plenary","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial\",\"authors\":\"J. Ledermann, N. Colombo, A. Oza, K. Fujiwara, M. Birrer, L. Randall, E. Poddubskaya, G. Scambia, YV Shparyk, M. Lim, J. Sohn, K. Yonemori, R. Stewart, Xijun Zhang, J. P. Smith, C. Linn, B. Monk\",\"doi\":\"10.1136/ijgc-2020-igcs.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":254448,\"journal\":{\"name\":\"Oral Plenary\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Plenary\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2020-igcs.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Plenary","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2020-igcs.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial